Press Releases

Date Title and Summary Additional Formats
Toggle Summary Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma  IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy , for AML and Multiple Myeloma IND Cleared Read All » View HTML
Toggle Summary SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer, Read All » View HTML
Toggle Summary SAN DIEGO , July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable Tumor Read All » View HTML
Toggle Summary FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Read All » View HTML
Toggle Summary SAN DIEGO , June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”)  (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All » View HTML
Toggle Summary SAN DIEGO , June 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All » View HTML
Toggle Summary SAN DIEGO , June 08, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has Read All » View HTML
Toggle Summary Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma Off-the-shelf NK Cell Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Functional Read All » View HTML
Toggle Summary Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates First Patient Treated with FT596, the First-ever Cellular Immunotherapy Engineered with Three Active Anti-tumor Modalities Second FT596 IND Allowed by FDA for Relapse Prevention after Read All » View HTML
Toggle Summary SAN DIEGO , May 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the retirement of Amir Nashat , Sc.D., Managing Read All » View HTML
Toggle Summary SAN DIEGO , May 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB Proprietary Binding Domains Shown to Overcome MICA/B Shedding, a Common Mechanism of Tumor Cell Escape Broadly Observed Across Solid Tumors Exclusive License Agreement with Read All » View HTML
Toggle Summary ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates ꟷ ꟷ Fate to receive $50 million upfront payment and $50 million equity investment, plus full funding for the research and Read All » View HTML
Toggle Summary SAN DIEGO , April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been treated in the Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.